Clinical Trials
| Cancer Type: Prostate | |
| Description: A Phase II Study of CNTO 328, A Monoclonal Antibody Against Interleukin-6 (IL-6), in Patients with Hormone Refractory Prostate Cancer | |
| Entity Approving The Trial: Southwest Oncology Group (SWOG) |
|
| Phase: II | |
| Site-Wide Accrual Goal: 40 | |
| Related Files | |
| No related files found. | |
| Related Links | |
| No related links found. |
 |
 |
|
